CombinatoRx says CRx-102 improves pain in osteoarthritis study

By Elaine Rigoli

Tampa, Fla., June 22 - CombinatoRx, Inc. announced additional results of its randomized, blinded, placebo-controlled phase 2 clinical trial of CRx-102 in patients with osteoarthritis of the hand.

CRx102 demonstrated a statistically significant mean improvement in pain relief, the primary endpoint of the study, as well as improvements in additional clinical measures including stiffness, physical function, joint pain and patient global assessment scores.

CRx-102 was well-tolerated with no serious adverse events reported in patients treated in this study, according to a news release.

There were no increases in infection or blood-glucose levels observed in the CRx-102 treated population as compared to a placebo.

CombinatoRx is a biopharmaceutical company located in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.